GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Price-to-Funds-From-Operations

CLLS (Cellectis) Price-to-Funds-From-Operations : (As of Mar. 03, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Cellectis Business Description

Industry
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.